ModifiedColorado Rocky Mountain Health PlansPolicy CS2026D0081P

Sodium Hyaluronate (Intra-articular) — Medical Benefit Coverage Criteria

Defines medical benefit coverage, preferred products, and authorization criteria for intra-articular sodium hyaluronate injections for knee osteoarthritis for Colorado Rocky Mountain Health Plans; includes FDA-labeled products, dosing courses, and diagnostic/coding references in this part of the policy.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicySodium Hyaluronate (Intra-articular) — Medical Benefit Coverage Criteria

Policy CodePolicy CS2026D0081P

Change TypeAdded product contingencyupdated product list and coding

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis, prior conservative therapy (>=3 months) or intolerance, functional pain, and product/dosing per FDA labeling.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate Hymovis One is contingent on the Preferred Product Criteria and Diagnosis-Specific Criteria.

Revised list of FDA approved sodium hyaluronate products and their respective FDA labeled dosage per treatment course per joint; added Hymovis One for 1 injection per joint.

Removed language indicating the preferred product criteria for sodium hyaluronate in this section applies to the states of Minnesota (MN) and Mississippi (MS).

Removed content/language pertaining to the state of Louisiana.

Revised description for HCPCS code J7322.

Updated FDA and References sections to reflect the most current information and archived previous policy version CS2026D0081O.

16+FDA-labeled products referenced

every 6 monthsInitial/continuation frequency

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Clinical Indications

Initial Therapy — Initial Authorization (Sodium Hyaluronate-Naïve Patients)

Initial Authorization (Sodium Hyaluronate-Naïve Patients): Covered when ALL of the following are met

Initial authorization criteria: Diagnosis of knee osteoarthritis; and the member has not responded adequately to conservative therapy (e.g., physical therapy, NSAIDs, acetaminophen, topical capsaicin, or intra-articular steroid injection) with no functional improvement after at least 3 months, or the member is unable to tolerate conservative therapy due to adverse side effects; and the member reports pain that interferes with functional activities (e.g., ambulation, prolonged standing); and the pain is attributed to degenerative joint disease/primary osteoarthritis of the knee; and there are no contraindications to the injections (e.g., active joint infection, bleeding disorder); and dosing is in accordance with U.S. FDA‑approved labeling; and initial authorization is for a single injection course once per joint for 6 months

Continued Therapy — Reauthorization/Continuation

Reauthorization/Continuation: Covered when ALL of the following are met

Reauthorization criteria: Diagnosis of knee osteoarthritis; and documentation of positive clinical response to the prior hyaluronan injection course (e.g., significant pain relief); and pain has recurred; and at least 6 months have passed since the prior course for the respective joint; and dosing is in accordance with U.S. FDA‑approved labeling; and continuing authorization is for a single injection course once per joint for 6 months

Preferred Product Exceptions — Preferred Product Criteria

Preferred Product Criteria: Use of non-preferred products is medically necessary only when ONE of the following two grouped conditions is met

Clinical nonresponse exception: History of a trial of adequate dose and duration of Durolane, Euflexxa, and Gelsyn-3 resulting in minimal clinical response; and physician attests that, in their clinical opinion, the clinical response would be expected to be superior with the requested non-preferred product

Requires documentation of trial and physician attestation

Failure/contraindication/intolerance exception: History of failure, contraindication, or intolerance to Durolane, Euflexxa, and Gelsyn-3; and physician attests that the same failure, contraindication, or intolerance would not be expected to occur with the requested non-preferred product

Requires physician attestation

Not Medically Necessary / Exclusions

Unproven or excluded indications: Intra-articular injections of sodium hyaluronate are unproven and not medically necessary for indications other than knee osteoarthritis (examples include hip osteoarthritis, temporomandibular joint osteoarthritis, temporomandibular joint disc displacement); and hyaluronic acid gel preparations for improving skin appearance, contouring, or reducing depressions (acne scars, wrinkles) are cosmetic and not covered.

Knee osteoarthritis — Evidence-supported scenarios and limitations

Evidence-supported scenarios and limitations

Knee OA: Multiple randomized trials and systematic reviews demonstrate small to modest improvements in pain and function with intra‑articular hyaluronate in symptomatic knee osteoarthritis; comparative trials show similar efficacy across products though effect sizes and duration vary; local adverse events differ by product in some studies.

References include Juni et al. (660 patients) and AHRQ/systematic reviews

Shoulder — Shoulder indications and evidence quality

Shoulder indications and evidence quality

Shoulder OA / rotator cuff pathology: Systematic reviews and randomized trials report improvements in pain and function after intra‑articular HA for glenohumeral OA and rotator cuff pathology, but heterogeneity, small sample sizes, and improvements in control groups limit definitive conclusions; further RCTs are needed.

Hip — Hip indications and conflicting trial results

Hip indications and conflicting trial results

Hip OA: Evidence is mixed: some small prospective studies suggest benefit, but a multicenter placebo randomized trial found no difference between a single intra‑articular HA injection and placebo at 3 months; VA/DoD guidance does not recommend IA hyaluronate for hip OA.

Ankle — Ankle and other joints

Ankle and other joints

Ankle OA: Data for ankle osteoarthritis are limited and generally low quality; small studies show mixed results and a double‑blind placebo randomized trial found no difference between a single HA injection and saline at 6–12 weeks; systematic reviews conclude insufficient evidence to support routine use.

Temporomandibular joint — Temporomandibular joint (TMJ) disorders

Temporomandibular joint (TMJ) disorders

TMJ disorders: Randomized trials and systematic reviews suggest possible short‑term benefit of intra‑articular HA for TMJ pain and function, but evidence is insufficient and does not demonstrate superiority over corticosteroid injections or appliances; additional well‑designed trials are needed.

Rheumatoid arthritis — Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA)

RA: Small trials and pooled analyses show some improvement in pain and inflammation with HA in RA-affected joints in limited studies, but biological plausibility is uncertain and larger randomized trials are needed before routine use is supported.

Glottic insufficiency — Glottic insufficiency / vocal fold medialization

Glottic insufficiency / vocal fold medialization

Unilateral vocal fold paralysis/insufficiency (UVFP): Multiple small randomized and prospective studies report improved voice outcomes and quality of life after intracordal HA injections (office or EMG/LEMG guided); outcomes show short‑to‑medium term benefit and many patients have durable response, though high‑quality comparative trials vs other injectables are limited.

Some cross‑linked preparations may provide durability ~4–6 months; use in the larynx may be off‑label for some products

Coverage considerations — Coverage considerations based on evidence and guideline statements in this document part:

Coverage considerations based on evidence and guideline statements in this document part:

Osteoarthritis — intra-articular HA: Consider HA injections only after failure of conservative therapy (exercise, simple analgesics) and with shared decision‑making because overall benefit is limited; note AAOS does not recommend routine viscosupplementation and ACR conditionally recommends against IA HA for knee and first CMC OA, and strongly recommends against use in hip OA.

FDA has approved multiple HA devices with product‑specific regimens

Injection laryngoplasty — HA for UVFP: HA injection laryngoplasty may be considered for temporary medialization in patients with unilateral vocal fold paralysis when medium‑term improvement (~4–6 months) is desired; evidence is limited and variable in quality.

Some laryngeal uses are off‑label

Product contingent coverage — Coverage for specific sodium hyaluronate products is subject to Preferred Product Criteria and Diagnosis‑Specific Criteria

Coverage for specific sodium hyaluronate products is subject to Preferred Product Criteria and Diagnosis‑Specific Criteria

Hymovis One coverage: Coverage for Hymovis One is contingent on meeting the policy's Preferred Product Criteria and Diagnosis‑Specific Criteria

Detailed product‑specific criteria are in referenced policy sections

Hyaluronic acid gel preparations intended to improve the skin’s appearance, contour, or to fill depressions from acne, scars, injury, or wrinkles are classified as cosmetic procedures and are not covered under this policy.

The National Institute for Health and Care Excellence (NICE) guidance states that intra‑articular hyaluronan injections should not be offered for the management of osteoarthritis; jurisdictions or benefit plans that follow NICE recommendations may therefore exclude IA hyaluronan from coverage.

Use of sodium hyaluronate to alter skin contours or to fill wrinkles and depressions is considered a cosmetic intervention because these conditions are not functional impairments. Such uses are explicitly excluded from medical coverage in this policy.

Policy language referencing applicability to the state of Louisiana was removed in the 04/01/2026 revision. Additionally, prior statements that the preferred product criteria applied to Minnesota (MN) and Mississippi (MS) were removed. These changes are recorded in the policy’s Revision History and may affect operational application in those jurisdictions.

The policy does not support routine intra‑articular sodium hyaluronate for non‑knee joints. Evidence for hip osteoarthritis is mixed with a multicenter placebo RCT showing no benefit for a single IA HA injection, and ankle studies include small RCTs with inconsistent results. Temporomandibular joint indications likewise lack high‑quality evidence. For these joints the policy treats IA hyaluronate as unproven / not medically necessary absent robust supporting documentation and prior conservative therapy trials.

Randomized controlled trial data for single‑injection HA in hip and ankle OA do not demonstrate consistent benefit: a multicenter placebo RCT in hip OA found no difference between single IA‑HA and placebo at 3 months, and a double‑blind RCT in ankle OA showed no significant difference between a single HA injection and saline at 6–12 weeks. These findings support the policy’s noncoverage stance for many single‑injection regimens in these joints without clear justification.

Major guideline bodies express caution about viscosupplementation: the American Academy of Orthopaedic Surgeons (AAOS) does not support routine use of IA hyaluronic acid for knee osteoarthritis, and the American College of Rheumatology (ACR) issues a conditional recommendation against IA hyaluronic acid for knee and first CMC OA and a strong recommendation against use in hip OA. These guideline positions inform the policy’s preference for conservative therapies and shared decision‑making.

This policy is informational and must be applied in the context of the applicable federal, state, and contractual benefit plan terms. In the event of a conflict, the federal, state, or contractual requirements for benefit plan coverage govern; providers should verify benefit plan eligibility and any plan‑specific tools (e.g., InterQual) prior to requesting authorization.

Initial Therapy Requirements and Product Dosing

Initial Therapy — Initial authorization requirements for sodium hyaluronate-naïve patients

Initial authorization requirements for sodium hyaluronate-naïve patients

Initial therapy nodes: Diagnosis of knee osteoarthritis; and failed or intolerant to conservative therapy for at least 3 months (e.g., PT, NSAIDs, acetaminophen, topical capsaicin, or IA steroid) with no functional improvement, or documented intolerance; and pain interferes with functional activities; and no contraindications; and dosing per FDA labeling; and initial authorization limited to a single injection course once per joint for 6 months>= 3 months

Prior authorization required

Initial therapy — Initial use and expected outcomes

Initial use and expected outcomes

Initial IA HA for knee OA: Randomized trials typically use 1 cycle (single or multi‑injection courses) with outcomes measured at 3–6 months; expect small to modest reductions in pain and improvement in function; some patients may require repeat cycles for persistent symptoms.

Reauthorization and Repeat Dosing

Continuation Therapy — Reauthorization rules for repeat courses

Reauthorization rules for repeat courses

Reauthorization nodes: Documentation of positive clinical response to prior course; recurrence of pain; at least 6 months since prior course for the respective joint; dosing per FDA labeling; authorization limited to a single injection course once per joint for 6 months>= 6 months

Continuation/Repeat dosing — Repeat cycles and multiple injections

Repeat cycles and multiple injections

Repeat cycles: Some knee trials offered a second cycle during months 7–12; for vocal fold injections, many patients had single durable injections while some required repeat injections at variable intervals; second cycles may show increased local adverse events with some products.

Document prior response and timing

Preferred Product Step Therapy and Exceptions

Requirement	Details
Step required
Members receiving non-preferred sodium hyaluronate products must have a documented trial of each preferred product (Durolane, Euflexxa, and Gelsyn-3) prior to continuation of the non-preferred product unless an exception is met (see exceptions).

Requirement	Details
Conservative therapy documented
For non-knee indications or joints with limited supporting evidence (e.g., shoulder, hip, ankle), prior trials of conservative treatments (such as physical therapy, simple analgesics/NSAIDs/acetaminophen, topical agents, and intra-articular corticosteroid where appropriate) should be documented and show inadequate response or intolerance before authorization is considered.

Guideline consideration	Application in policy
Prefer alternatives recommended by guidelines
Because guidelines (ACR, AAOS) and evidence syntheses favor alternatives (for example, IA glucocorticoids, exercise and other conservative measures) and do not support routine viscosupplementation, providers should document trials of recommended alternative therapies and shared decision-making before routine use of HA for knee OA.

Product	Coverage condition
Hymovis One
Coverage for Hymovis One is contingent on meeting the policy's Preferred Product Criteria and the Diagnosis‑Specific Criteria; authorization requires documentation that these criteria are satisfied per the policy (product-specific contingency).

Per-Course Injection Limits by Product

inv-65: Durolane — 1 injection per course

ProductDurolane

Quantity limit1 injection per course

Source noteFDA‑labeled single‑injection regimen per product labeling

inv-66: Euflexxa — 3 injections per course

ProductEuflexxa

Quantity limit3 injections per course

Source noteFDA‑labeled regimen per product labeling

Procedure, Billing, and Diagnosis Codes

Applicable CPT CodesCPT

20605	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; without ultrasound guidance
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; with ultrasound guidance; with permanent recording and reporting
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting

Applicable HCPCS/J CodesHCPCS

J3490	Unclassified drugs
J7318	Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
J7320	Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
J7321	Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose
J7322	Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular injection, 1 mg
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose

1–10 of 14

1/2

Applicable ICD-10 CodesICD-10Covered

M13.0	Polyarthritis, unspecified
M17.0	Bilateral primary osteoarthritis of knee
M17.10	Unilateral primary osteoarthritis, unspecified knee
M17.11	Unilateral primary osteoarthritis, right knee
M17.12	Unilateral primary osteoarthritis, left knee
M17.2	Bilateral post-traumatic osteoarthritis of knee
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee
M17.31	Unilateral post-traumatic osteoarthritis, right knee
M17.32	Unilateral post-traumatic osteoarthritis, left knee
M17.4	Other bilateral secondary osteoarthritis of knee

1–10 of 12

1/2

No explicit billing or diagnosis codes in this document segmentmixed

No codes listed

Applicable HCPCSHCPCS

J7322

HCPCS code description revised (policy notes revision to description)

inv-27: Conservative therapy duration — >= 3 months

RequirementConservative therapy duration must be at least 3 months before initial authorization

Examples of conservative therapyPhysical therapy, NSAIDs, acetaminophen, topical capsaicin, or intra‑articular corticosteroid

DocumentationClinical record must show inadequate response or intolerance to conservative therapy

inv-28: Minimum interval between courses — >= 6 months

Minimum intervalAt least 6 months must have passed since the prior course for the respective joint before reauthorization

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Recommended for Non‑Knee Joints

Prior authorization required for intra-articular sodium hyaluronate requested for non‑knee joints (hip, ankle, shoulder, other). Evidence for effectiveness in hip and ankle is mixed or insufficient; prior authorization may be requested to document medical necessity and prior conservative therapy.

Prior authorization recommended for hip and ankle OA due to limited/contradictory evidence (see supporting clinical trials and guidelines).
For shoulder injections, clinical improvements are reported but placebo effects and limited RCT data may prompt prior authorization review.

Documentation Required

Product‑Specific Regimen Verification

Verify that the requested product’s dosing regimen matches the FDA‑approved labeling. Some sodium hyaluronate products have single‑injection approvals while others require multi‑injection courses; prior authorization may require the requested number/timing of injections to align with product labeling.

Definitions and Product List

inv-47: Component of synovial fluid used for intra-articular viscosupplementation — Sodium hyaluronate (HA) / hyaluronan

ComponentSodium hyaluronate (HA) / hyaluronan

RoleNormal component of synovial fluid that lubricates joints and absorbs shock

SourcesDerived from bacterial fermentation or extracted from avian products; varies by molecular weight and cross‑linking

inv-48: Viscosupplementation definition — Intra-articular injection of hyaluronic acid products to improve joint lubrication and reduce pain in osteoarthritis

DefinitionIntra-articular injection of hyaluronic acid products to improve joint lubrication and reduce pain in osteoarthritis

Expected outcomesMay provide small to modest improvement in pain and function for knee OA; timing of effect often peaks around 8 weeks

Setting and Procedure Considerations

Billing Rule

Procedure coding and site‑of‑care depends on CPT code and joint

Procedure codes for arthrocentesis and injection are provided for reference; the appropriate setting (office, infusion center, or hospital outpatient) depends on the CPT code for the joint and usual practice.

CPT codes include 20605, 20606 (intermediate joints), and 20610, 20611 (major joints).
Selection of site of care should align with the chosen CPT code and standard practice.

Note

Office setting acceptable for intracordal and many IA injections

Intracordal (laryngeal) hyaluronic acid injections and many intra‑articular viscosupplementation procedures can be performed in the office setting (often with LEMG/EMG guidance); IA injections may also be performed in outpatient settings as appropriate.

Clinical Evidence, Guidelines, and References

Sodium hyaluronate (hyaluronic acid, HA) is a naturally occurring component of synovial fluid used for intra‑articular viscosupplementation to supplement joint lubrication. FDA approvals are limited to knee osteoarthritis; products differ by molecular weight and cross‑linking and have variable evidence for clinical benefit.

Selected clinical trials and references cited in the background include randomized and prospective studies of HA in knee OA and vocal fold injection laryngoplasty; reference listings and product package inserts are included in the policy’s References and FDA sections for detailed study citation and device labeling.

Guideline assessments and evidence‑quality statements note limited or mixed benefit for IA hyaluronic acid: the ACR conditionally recommends against IA HA for knee and first CMC OA and strongly against hip OA; AAOS does not recommend routine viscosupplementation for knee OA; and NICE advises against offering IA hyaluronan for OA. These positions reflect the variable quality and heterogeneity of RCT evidence.

Policy Updates and Change Log

2026-04-01removal

Removed content/language pertaining to the state of Louisiana and removed prior applicability language for Minnesota and Mississippi.

2026-04-01addition

Added language indicating that coverage for Hymovis One is contingent on meeting the policy's Preferred Product Criteria and Diagnosis‑Specific Criteria (operational impact on Hymovis One coverage).

2026-04-01revision

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicySodium Hyaluronate (Intra-articular) — Medical Benefit Coverage Criteria

Policy CodePolicy CS2026D0081P

Change TypeAdded product contingencyupdated product list and coding

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis, prior conservative therapy (>=3 months) or intolerance, functional pain, and product/dosing per FDA labeling.

SourceLink

On This Page

Initial IA therapy dosing — Product-specific initial dosing regimens as per FDA labeling:

Product-specific initial dosing regimens as per FDA labeling:

Device-labeled regimens: Products have differing FDA‑approved regimens: examples include Hyalgan (5 injections), Synvisc/Euflexxa (3 injections), Supartz (3–5 injections), Orthovisc (3–4 injections), and single‑injection products such as Synvisc One, Gel‑One, Monovisc, Durolane, and Hymovis One.

Verify product labeling for exact dosing per joint

FDA‑labeled dosing per product — Initial therapy guidance references FDA‑labeled dosages per treatment course per joint and product‑specific dosing; Hymovis One added as ...

Initial therapy guidance references FDA‑labeled dosages per treatment course per joint and product‑specific dosing; Hymovis One added as single‑injection per joint.

FDA‑labeled dosing: Policy lists FDA‑approved sodium hyaluronate products and their labeled dosage per treatment course per joint; Hymovis One is noted as a single injection per joint; see product labeling for exact regimen and number of injections per course.

Exact dosing table in policy

Laryngeal HA continuation — Follow-up injections and durability considerations for laryngeal HA IL:

Follow-up injections and durability considerations for laryngeal HA IL:

Repeat laryngoplasty: Some patients required second intracordal HA injections (examples: Gotxi‑Erezuma reported 6 of 28 patients required second injections); cross‑linked or larger‑particle HA preparations may provide durability of approximately 4–6 months in some studies.

Document prior response and interval

Note

Evidence‑Based Guideline Conflicts

Professional society guidance is mixed and may argue against routine use of intra‑articular hyaluronate. AAOS does not recommend routine viscosupplementation for knee OA; ACR conditionally recommends against IA HA for knee and first CMC OA and strongly recommends against use for hip OA. NICE guidance advises IA hyaluronan injections should not be offered. These guideline positions may affect coverage determinations and prior authorization decisions.

AAOS: does not support routine use for knee OA (2nd and 3rd edition guidance).
ACR: conditionally recommended against IA HA for knee and first CMC; strongly recommended against for hip OA.
NICE: advises against offering IA hyaluronan for OA.

Denial Risk

Contraindicated Patients

Do not administer sodium hyaluronate to patients with known hypersensitivity to hyaluronate preparations or to avian/avian‑derived products (eggs, feathers, poultry). Orthovisc is exempt from the avian‑derived allergy contraindication but has a separate contraindication for hypersensitivity to gram‑positive bacterial proteins. Do not inject in the presence of active joint or skin infection at the injection site or into patients with bleeding disorders without appropriate precautions.

Contraindication: known allergy to hyaluronate preparations or avian‑derived products (except Orthovisc).
Orthovisc specific: do not use in patients with hypersensitivity to gram‑positive bacterial proteins.
Do not inject if there is active infection at the injection site or joint; avoid if uncontrolled bleeding disorder.

Documentation Required

Clinical Trial and Prior Therapy Documentation

Document prior conservative therapies, trial details, and clinical trial evidence summaries when requesting authorization. Include dates, duration, response, and reasons for intolerance or failure of therapies. Summaries of relevant clinical trials may be requested for non‑knee indications or off‑label uses.

Record trial of conservative therapy (PT, NSAIDs, acetaminophen, topical capsaicin) with duration (≥ 3 months) and response.
If prior IA glucocorticoid injection was used, document timing and response.
For non‑knee joints, include supporting clinical trial summaries and rationale for use given limited evidence.

Documentation Required

Required Documentation (Supporting Content)

Include the following supporting documentation with prior authorization requests: diagnosis (site‑specific OA), description of functional impairment and pain severity, documentation of prior conservative and alternative therapies and responses, product name and specific device/brand requested, number of injections per FDA labeling, and absence of infection at the injection site.

Diagnosis of knee OA (or specific joint) and attribution of symptoms to degenerative joint disease.
Functional impact statement (eg, limitation in ambulation, standing, activities of daily living).
Dates and outcomes of conservative therapy trials or documented intolerance/contraindication.
Product/device name and HCPCS/NDC as applicable, and number of injections requested consistent with FDA labeling.
Documentation that there is no active infection at the injection site and no other contraindications.

Documentation Required

Documentation of Benefit Plan Eligibility

Verify and document that the member’s federal, state, or contractual benefit plan allows coverage for the requested sodium hyaluronate. In case of conflict, federal/state/contractual requirements govern the decision. Benefit verification may be required prior to authorization.

Confirm plan-specific coverage rules and any state‑specific limitations or preferred product criteria.
If federal/state/contractual terms differ from this policy, follow those governing terms.

Step Therapy

Preferred Product Step‑Therapy

Preferred‑product step‑therapy applies: members on non‑preferred sodium hyaluronate products will generally be required to trial preferred products (eg, Durolane, Euflexxa, Gelsyn‑3) unless they meet the medical exceptions criteria (failure, intolerance, contraindication, or physician attestation of superior expected response).

Coverage for certain products (eg, GenVisc 850, Hyalgan, Supartz, Visco‑3, Hymovis, Hymovis One, Orthovisc, Synvisc/Synvisc‑One, GelOne, Monovisc, Triluron, TriVisc, Synojoynt) is contingent on meeting Preferred Product and Diagnosis‑Specific Criteria.
Medical exception options: trial with inadequate response to Durolane/Euflexxa/Gelsyn‑3, or documented failure/contraindication/intolerance to these preferred agents with clinician attestation that the alternative will be tolerated or effective.

Documentation Required

Consider Prior Conservative/Alternative Therapy

Consider and document alternative conservative therapies prior to IA hyaluronate for knee OA—guidelines favor intra‑articular glucocorticoid injections and other conservative measures. For non‑knee joints, require documented trials of conservative therapy (PT, analgesics, steroid injections) and rationale for hyaluronate use given limited evidence.

For knee OA: document ≥ 3 months of conservative therapy or intolerance/contraindication.
For shoulder, hip, and ankle: require trials of physical therapy, analgesics, and intra‑articular steroids where appropriate and document lack of adequate response.

inv-53: Sodium hyaluronate products list — FDA‑approved products (e.g., Supartz, Synvisc, Hyalgan, Gel-One, Orthovisc, Monovisc, GelSyn-3, GenVisc 850, Hymovis, Durolane, Visco-3, TriVisc, Synojoynt, Triluron, Euflexxa, Hymovis One)

ListSupartz, Synvisc, Hyalgan, Gel‑One, Orthovisc, Monovisc, GelSyn‑3, GenVisc 850, Hymovis, Durolane, Visco‑3, TriVisc, Synojoynt, Triluron, Euflexxa, Hymovis One

SourceFDA‑approved sodium hyaluronate products as listed in policy and package inserts

NoteProduct‑specific dosing/regimens and single vs multi‑injection courses vary by product labeling

Note

Office or outpatient setting for injection laryngoplasty and IA viscosupplementation

Injection laryngoplasty may be performed in the office; intra‑articular viscosupplementation is typically performed in the office/clinic or hospital outpatient setting depending on joint and procedure codes.

Office‑based IL with HA has published series and trials showing procedural feasibility and outcomes.
Choose setting consistent with procedure code (CPT 20605–20611) and standard practice.